[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432519":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":27,"locations":36,"responsibleParty":49,"collaborators":27,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":27,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":78,"whyStopped":27,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"ARNI-Sacubitril-Valsartan","EXPERIMENTAL","patients randomized to angiotensin receptor neprilysin inhibitor (ARNI) group will receive 2 doses of angiotensin receptor blocker (ARB) to ensure a minimum 36-hour washout period prior to initiation of ARNI therapy, and then be started with the first dose or sacubitril-valsartan.",[13,14],"Drug: Sacubitril-Valsartan","Drug: Valsartan",{"label":16,"type":17,"description":18,"interventionNames":19},"ACEI-Enalapril","ACTIVE_COMPARATOR","patients randomized to angiotensin-converting enzyme inhibitor (ACEI) group will directly start with the first dose of enalapril",[20],"Drug: Enalapril",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Sacubitril-Valsartan","After initiation of the treatment of sacubitril\u002Fvalsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24\u002F26 mg, 49\u002F51 mg and 97\u002F103 mg, twice daily)",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Enalapril","After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)",[16],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Valsartan","For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.",[9],[37],{"facility":5,"status":27,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":27},"Chengdu","Sichuan","621000","China","CN",{"type":44,"coordinates":45},"Point",[46,47],104.06667,30.66667,{"lat":47,"lon":46},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Yong He","Professor","100432519","phase-3-the-effects-of-sacubitril-valsartan-vs-enalapril-on-left-ventricular-remodeling-in-st-elevation-myocardial-infarction-100432519",false,"NCT04912167","The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction","A Multi-center, Prospective Randomized Controlled Trial on the Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction","PERI-STEMI","Inclusion Criteria:\n\n* Aged between 18 - 75 years old\n* First-time ST-segment elevation myocardial infarction based on the newest ESC guidelines\n* Timely primary percutaneous coronary intervention within 12 hours from onset\n* Written informed consent acquired\n\nExclusion Criteria:\n\n* Known history of or persistent clinical chronic heart failure prior to randomization\n* Previous use of ARNI, or intolerance or contraindications to study drugs including ARNI or ACEI\n* History of significant chronic coronary obstruction and adverse ventricular remodeling\n* History of any cardiomyopathy, valvular heart disease, congenital heart disease, stent or CABG, or planned open-heart surgery within 3 months\n* History of hepatic impairment or history of cirrhosis with evidence of portal hypertension\n* History of chronic renal dysfunction, or eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n* History of malignancy and with a life span less than one year\n* Patients with a known history of angioedema related to previous ACEIs\u002FARB therapy.\n* With contraindication to MRI examination (pacemaker and claustrophobia) or cannot finish breath-holding when lying on the examination bed\n* Pregnancy or nursing women","ALL","18 Years","75 Years",{"count":65,"type":66},376,"ESTIMATED","INTERVENTIONAL",[69],"PHASE3","The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial infarction (STEMI) than enalapril.",[72],"STEMI",[74,75,76,77],"ST-elevation myocardial infarction (STEMI)","cardiovascular magnetic resonance (CMR)","angiotensin receptor neprilysin inhibitor (ARNI)","angiotensin-converting enzyme inhibitor (ACEI)","NOT_YET_RECRUITING","2021-09-23",{"date":81,"type":82},"2021-09-29","ACTUAL",{"date":84,"type":66},"2021-11",{"date":86,"type":66},"2026-06",{"name":5,"class":6},1]